Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.51 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.51 |
| ▸ | MTOR | P42345 | 2/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.51 |
| ▸ | CLK1 | P49759 | 2/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.51 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.51 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 2/20 | 0.50 |
| ▸ | GAK | O14976 | 1/20 | 0.50 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2882656 | 1.00 | HTT (0.53) | HTTPIK3CDCSNK2A2PIK3CAPIK3CB | |
| SCHEMBL2884702 | 0.90 | CISD1 (0.54) | HTTPIK3CDCSNK2A2PIK3CAPIK3CB | |
| SCHEMBL2882270 | 0.89 | CISD1 (0.53) | HTTPIK3CDCSNK2A2PIK3CAPIK3CB | |
| SCHEMBL2882271 | 0.89 | CISD1 (0.53) | HTTPIK3CDCSNK2A2PIK3CAPIK3CB | |
| SCHEMBL2880770 | 0.88 | CISD1 (0.52) | PIK3CDCSNK2A2PIK3CAPIK3CBMTOR | |
| SCHEMBL2880773 | 0.88 | CISD1 (0.52) | PIK3CDCSNK2A2PIK3CAPIK3CBMTOR | |
| SCHEMBL2876848 | 0.88 | PIK3CD (0.53) | HTTPIK3CDCSNK2A2PIK3CAPIK3CB | |
| SCHEMBL2876844 | 0.88 | PIK3CD (0.53) | HTTPIK3CDCSNK2A2PIK3CAPIK3CB | |
| SCHEMBL2882472 | 0.87 | MEN1 (0.53) | PIK3CDCSNK2A2PIK3CAPIK3CBMTOR | |
| SCHEMBL2882471 | 0.87 | MEN1 (0.53) | PIK3CDCSNK2A2PIK3CAPIK3CBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | claimed |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | MERCK SERONO SA (CH) | 2009-02-12 | — | — | US | claimed |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2006-06-08 | — | — | US | claimed |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) | 2005-10-06 | — | — | US | claimed |
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | disclosed |
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | LABORATOIRES SERONO S.A. (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20080306057-A1 | P13K Inhibitors for the Treatment of Endometriosis | LABORATORIES SERONO SA (CH) | 2008-12-11 | — | — | US | disclosed |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2006-06-08 | — | — | US | disclosed |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) | 2005-10-06 | — | — | US | disclosed |
| EP-1531813-A1 | USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY | Applied Research Systems ARS Holding N.V. (AN) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004006916-A1 | USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | ZAP70, BRCA1, ZYX | HTT 1649/4885PIK3CD 769/4885CSNK2A2 4143/4885 |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | PDPK1, PRKD3, PRKD1 | HTT 3492/4885PIK3CD 39/4885CSNK2A2 388/4885 |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | CATSPER1, PI4KB, MAN2B2 | HTT 3887/4885PIK3CD 118/4885CSNK2A2 338/4885 |
| US-20080306057-A1 | P13K Inhibitors for the Treatment of Endometriosis | PDPK1, PIK3R4, MAP3K3 | HTT 2107/4885PIK3CD 43/4885CSNK2A2 583/4885 |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | BRCA1, ZAP70, F13B | HTT 1583/4885PIK3CD 771/4885CSNK2A2 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.